Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Childhood obesity and leukocyte telomere length.

Lamprokostopoulou A, Moschonis G, Manios Y, Critselis E, Nicolaides NC, Stefa A, Koniari E, Gagos S, Charmandari E.

Eur J Clin Invest. 2019 Oct 14:e13178. doi: 10.1111/eci.13178. [Epub ahead of print]

PMID:
31610015
2.

Glucocorticoid Resistance.

Nicolaides NC, Charmandari E.

Exp Suppl. 2019;111:85-102. doi: 10.1007/978-3-030-25905-1_6. Review.

PMID:
31588529
3.

Pythagorean self-awareness intervention: A novel cognitive stress management technique for body weight control.

Simos DS, Kokkinos A, Tentolouris N, Dimosthenopoulos C, Mantzou E, Artemiadis A, Bacopoulou F, Nicolaides NC, Kosta O, Chrousos GP, Darviri C.

Eur J Clin Invest. 2019 Oct;49(10):e13164. doi: 10.1111/eci.13164. Epub 2019 Sep 16.

PMID:
31421060
4.

Transcriptomics in tissue glucocorticoid sensitivity.

Nicolaides NC, Polyzos A, Koniari E, Lamprokostopoulou A, Papageorgiou I, Golfinopoulou E, Papathanasiou C, Sertedaki A, Thanos D, Chrousos GP, Charmandari E.

Eur J Clin Invest. 2019 Aug;49(8):e13129. doi: 10.1111/eci.13129. Epub 2019 May 30.

PMID:
31091335
5.

A bullous-like lesion on the scalp in a neonate.

Nicolaides NC, Siahanidou T.

J Paediatr Child Health. 2019 Mar;55(3):371. doi: 10.1111/jpc.2_14316. No abstract available.

PMID:
30828937
6.

A bullous-like lesion on the scalp in a neonate.

Nicolaides NC, Siahanidou T.

J Paediatr Child Health. 2019 Mar;55(3):370. doi: 10.1111/jpc.1_14316. No abstract available.

PMID:
30828935
7.

Impact of a stress management program on weight loss, mental health and lifestyle in adults with obesity: a randomized controlled trial.

Xenaki N, Bacopoulou F, Kokkinos A, Nicolaides NC, Chrousos GP, Darviri C.

J Mol Biochem. 2018;7(2):78-84. Epub 2018 Oct 3.

8.

Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.

Kline JB, Fernando S, Ross EN, Grasso L, Nicolaides NC.

Eur J Immunol. 2018 Nov;48(11):1872-1882. doi: 10.1002/eji.201847707. Epub 2018 Oct 19.

PMID:
30144039
9.

Research update for articles published in EJCI in 2016.

Adlbrecht C, Blanco-Verea A, Bouzas-Mosquera MC, Brion M, Burtscher M, Carbone F, Chang TT, Charmandari E, Chen JW, Correia-Costa L, Dullaart RPF, Eleftheriades M, Fernandez-Fernandez B, Goliasch G, Gremmel T, Groeneveld ME, Henrique A, Huelsmann M, Jung C, Lichtenauer M, Montecucco F, Nicolaides NC, Niessner A, Palmeira C, Pirklbauer M, Sanchez-Niño MD, Sotiriadis A, Sousa T, Sulzgruber P, van Beek AP, Veronese N, Winter MP, Yeung KK, Bouzas-Mosquera A.

Eur J Clin Invest. 2018 Oct;48(10):e13016. doi: 10.1111/eci.13016. Epub 2018 Sep 16. Review. No abstract available.

PMID:
30099749
10.

Bilateral adrenal hyperplasia and NR3C1 mutations causing glucocorticoid resistance: Is there an association?

Nicolaides NC, Chrousos GP.

Eur J Endocrinol. 2018 Oct 12;179(5):C1-C4. doi: 10.1530/EJE-18-0471.

PMID:
30006372
11.

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.

Nicolaides NC, Schweizer C, Somers EB, Wang W, Fernando S, Ross EN, Grasso L, Hassan R, Kline JB.

Cancer Biol Ther. 2018 Jul 3;19(7):622-630. doi: 10.1080/15384047.2018.1449614. Epub 2018 Apr 25.

12.

HCV genetics and genotypes dictate future antiviral strategies.

Papageorgiou L, Vlachakis C, Dragoumani K, Raftopoulou S, Brouzas D, Nicolaides NC, Chrousos GP, Charmandari E, Megalooikonomou V, Vlachakis D.

J Mol Biochem. 2017;6:33-40. Epub 2017 Dec 10.

13.

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.

Wang W, Somers EB, Ross EN, Kline JB, O'Shannessy DJ, Schweizer C, Weil S, Grasso L, Nicolaides NC.

Cytogenet Genome Res. 2017;152(4):169-179. doi: 10.1159/000481213. Epub 2017 Oct 18.

PMID:
29041009
14.

CA125 effects on humoral immunosuppression.

Kline JB, Nicolaides NC.

Aging (Albany NY). 2017 Oct 3;9(10):2010-2011. doi: 10.18632/aging.101301. No abstract available.

15.

Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures.

Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW 4th, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS.

Oncotarget. 2017 Aug 5;8(40):66747-66757. doi: 10.18632/oncotarget.19965. eCollection 2017 Sep 15.

16.

Research update for articles published in EJCI in 2015.

Al-Daghri NM, Batzel JJ, Burgmann H, Carbone F, Charmandari E, Chrousos GP, Distelmaier K, Cvirn G, Dullaart RPF, Dumitrascu DL, Esteve-Pastor MA, Gervasini G, Goliasch G, Goswami N, Gruppen EG, Hernández-Mijares A, Kalantaridou SN, Krause R, Latini R, Makrigiannakis A, Marín F, Masson S, Montecucco F, Ndrepepa G, Nicolaides NC, Novelli D, Orasan OH, Qorbani M, Ratzinger F, Roessler A, Sabico S, Sciatti E, Stefanaki C, Stoner L, Tabatabaei-Malazy O, Tatar E, Toz H, Uslu A, Victor VM, Vizzardi E.

Eur J Clin Invest. 2017 Oct;47(10):775-788. doi: 10.1111/eci.12819. No abstract available.

PMID:
28960328
17.

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement.

Kline JB, Kennedy RP, Albone E, Chao Q, Fernando S, McDonough JM, Rybinski K, Wang W, Somers EB, Schweizer C, Grasso L, Nicolaides NC.

Oncotarget. 2017 Jul 7;8(32):52045-52060. doi: 10.18632/oncotarget.19090. eCollection 2017 Aug 8.

18.

The Role of S-Palmitoylation of the Human Glucocorticoid Receptor (hGR) in Mediating the Nongenomic Glucocorticoid Actions.

Nicolaides NC, Kino T, Roberts ML, Katsantoni E, Sertedaki A, Moutsatsou P, Psarra AG, Chrousos GP, Charmandari E.

J Mol Biochem. 2017;6(1):3-12. Epub 2017 Apr 15.

19.

Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes.

Nicolaides NC, Charmandari E.

Hormones (Athens). 2017 Apr;16(2):124-138. doi: 10.14310/horm.2002.1728. Review.

20.

Stress-Related and Circadian Secretion and Target Tissue Actions of Glucocorticoids: Impact on Health.

Nicolaides NC, Charmandari E, Kino T, Chrousos GP.

Front Endocrinol (Lausanne). 2017 Apr 28;8:70. doi: 10.3389/fendo.2017.00070. eCollection 2017. Review.

21.

Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer.

O'Shannessy DJ, Bendas K, Schweizer C, Wang W, Albone E, Somers EB, Weil S, Meredith RK, Wustner J, Grasso L, Landers M, Nicolaides NC.

Genomics. 2017 Jul;109(3-4):251-257. doi: 10.1016/j.ygeno.2017.04.006. Epub 2017 Apr 25.

22.

Paediatric stress: from neuroendocrinology to contemporary disorders.

Stavrou S, Nicolaides NC, Critselis E, Darviri C, Charmandari E, Chrousos GP.

Eur J Clin Invest. 2017 Mar;47(3):262-269. doi: 10.1111/eci.12724. Epub 2017 Feb 3. Review.

PMID:
28074555
23.

The effectiveness of a stress-management intervention program in the management of overweight and obesity in childhood and adolescence.

Stavrou S, Nicolaides NC, Papageorgiou I, Papadopoulou P, Terzioglou E, Chrousos GP, Darviri C, Charmandari E.

J Mol Biochem. 2016;5(2):63-70. Epub 2016 Jul 31.

24.

Novel antibody probes for the characterization of endosialin/TEM-1.

O'Shannessy DJ, Smith MF, Somers EB, Jackson SM, Albone E, Tomkowicz B, Cheng X, Park Y, Fernando D, Milinichik A, Kline B, Fulton R, Oberoi P, Nicolaides NC.

Oncotarget. 2016 Oct 25;7(43):69420-69435. doi: 10.18632/oncotarget.11018.

25.

Recent advances in the molecular mechanisms causing primary generalized glucocorticoid resistance.

Nicolaides N, Lamprokostopoulou A, Sertedaki A, Charmandari E.

Hormones (Athens). 2016 Jan-Mar;15(1):23-34. doi: 10.14310/horm.2002.1660. Review.

26.

Functional characterization of the hGRαT556I causing Chrousos syndrome.

Nicolaides NC, Skyrla E, Vlachakis D, Psarra AM, Moutsatsou P, Sertedaki A, Kossida S, Charmandari E.

Eur J Clin Invest. 2016 Jan;46(1):42-9. doi: 10.1111/eci.12563. Epub 2015 Dec 15.

PMID:
26541474
27.

Transient generalized glucocorticoid hypersensitivity.

Nicolaides NC, Lamprokostopoulou A, Polyzos A, Kino T, Katsantoni E, Triantafyllou P, Christophoridis A, Katzos G, Dracopoulou M, Sertedaki A, Chrousos GP, Charmandari E.

Eur J Clin Invest. 2015 Dec;45(12):1306-15. doi: 10.1111/eci.12554. Epub 2015 Nov 20.

PMID:
26479047
28.

Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.

Rybinski K, Imtiyaz HZ, Mittica B, Drozdowski B, Fulmer J, Furuuchi K, Fernando S, Henry M, Chao Q, Kline B, Albone E, Wustner J, Lin J, Nicolaides NC, Grasso L, Zhou Y.

Oncotarget. 2015 Sep 22;6(28):25429-40. doi: 10.18632/oncotarget.4559.

29.

A novel mutation of the hGR gene causing Chrousos syndrome.

Nicolaides NC, Geer EB, Vlachakis D, Roberts ML, Psarra AM, Moutsatsou P, Sertedaki A, Kossida S, Charmandari E.

Eur J Clin Invest. 2015 Aug;45(8):782-91. doi: 10.1111/eci.12470. Epub 2015 Jul 14.

PMID:
26031419
30.

Glucocorticoid Therapy and Adrenal Suppression.

Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2018 Oct 19.

31.

Adrenal Insufficiency.

Nicolaides NC, Chrousos GP, Charmandari E.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2017 Oct 14.

32.

Primary Generalized Glucocorticoid Resistance or Chrousos Syndrome.

Nicolaides NC, Kino T, Chrousos G, Charmandari E.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2017 Sep 10.

33.

Chrousos syndrome: from molecular pathogenesis to therapeutic management.

Nicolaides NC, Charmandari E.

Eur J Clin Invest. 2015 May;45(5):504-14. doi: 10.1111/eci.12426. Epub 2015 Mar 23. Review.

PMID:
25715669
34.

Stress, the stress system and the role of glucocorticoids.

Nicolaides NC, Kyratzi E, Lamprokostopoulou A, Chrousos GP, Charmandari E.

Neuroimmunomodulation. 2015;22(1-2):6-19. doi: 10.1159/000362736. Epub 2014 Sep 12. Review.

PMID:
25227402
35.
36.

Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy.

Nicolaides NC, O'Shannessy DJ, Albone E, Grasso L.

Front Oncol. 2014 Jun 13;4:141. doi: 10.3389/fonc.2014.00141. eCollection 2014. Review.

37.

Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins.

O'Shannessy DJ, Somers EB, Chandrasekaran LK, Nicolaides NC, Bordeaux J, Gustavson MD.

Oncotarget. 2014 Jun 30;5(12):3983-95.

38.

Circadian endocrine rhythms: the hypothalamic-pituitary-adrenal axis and its actions.

Nicolaides NC, Charmandari E, Chrousos GP, Kino T.

Ann N Y Acad Sci. 2014 May;1318:71-80. doi: 10.1111/nyas.12464. Review.

39.

Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.

Li C, Chacko AM, Hu J, Hasegawa K, Swails J, Grasso L, El-Deiry WS, Nicolaides N, Muzykantov VR, Divgi CR, Coukos G.

Cancer Biol Ther. 2014 Apr;15(4):443-51. doi: 10.4161/cbt.27825. Epub 2014 Feb 19.

40.

Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.

Chacko AM, Li C, Nayak M, Mikitsh JL, Hu J, Hou C, Grasso L, Nicolaides NC, Muzykantov VR, Divgi CR, Coukos G.

J Nucl Med. 2014 Mar;55(3):500-507. doi: 10.2967/jnumed.113.121905. Epub 2014 Feb 13.

41.

Adrenal insufficiency.

Charmandari E, Nicolaides NC, Chrousos GP.

Lancet. 2014 Jun 21;383(9935):2152-67. doi: 10.1016/S0140-6736(13)61684-0. Epub 2014 Feb 4. Review.

PMID:
24503135
42.

A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities.

Nicolaides NC, Roberts ML, Kino T, Braatvedt G, Hurt DE, Katsantoni E, Sertedaki A, Chrousos GP, Charmandari E.

J Clin Endocrinol Metab. 2014 May;99(5):E902-7. doi: 10.1210/jc.2013-3005. Epub 2014 Jan 31.

43.

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, Martinez BP, Chao Q, Zhou Y, Nicolaides NC, Kline JB, Grasso L.

Cancer Biol Ther. 2013 Nov;14(11):1032-8. doi: 10.4161/cbt.26106. Epub 2013 Aug 28.

44.

A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD.

Roberts ML, Kino T, Nicolaides NC, Hurt DE, Katsantoni E, Sertedaki A, Komianou F, Kassiou K, Chrousos GP, Charmandari E.

J Clin Endocrinol Metab. 2013 Apr;98(4):E790-5. doi: 10.1210/jc.2012-3549. Epub 2013 Feb 20.

45.

Characterization of the human folate receptor alpha via novel antibody-based probes.

O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Hamuro Y, Kohl TO, Forsyth TM, Smale R, Fu YS, Nicolaides NC.

Oncotarget. 2011 Dec;2(12):1227-43.

46.

Plasma proteomic analysis in obese and overweight prepubertal children.

Galata Z, Moschonis G, Makridakis M, Dimitraki P, Nicolaides NC, Manios Y, Bartzeliotou A, Chrousos GP, Charmandari E.

Eur J Clin Invest. 2011 Dec;41(12):1275-83. doi: 10.1111/j.1365-2362.2011.02536.x. Epub 2011 May 16.

PMID:
21569026
47.

Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B.

Drozdowski B, Zhou Y, Kline B, Spidel J, Chan YY, Albone E, Turchin H, Chao Q, Henry M, Balogach J, Routhier E, Bavari S, Nicolaides NC, Sass PM, Grasso L.

J Immune Based Ther Vaccines. 2010 Dec 21;8:9. doi: 10.1186/1476-8518-8-9.

48.

Advances in targeted therapeutic agents.

Nicolaides NC, Sass PM, Grasso L.

Expert Opin Drug Discov. 2010 Nov;5(11):1123-40. doi: 10.1517/17460441.2010.521496. Epub 2010 Oct 1. Review.

PMID:
22827748
49.

Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling.

Tomkowicz B, Rybinski K, Sebeck D, Sass P, Nicolaides NC, Grasso L, Zhou Y.

Cancer Biol Ther. 2010 Jun 1;9(11):908-15. Epub 2010 Jun 8.

PMID:
20484976
50.

The human glucocorticoid receptor: molecular basis of biologic function.

Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E.

Steroids. 2010 Jan;75(1):1-12. doi: 10.1016/j.steroids.2009.09.002. Epub 2009 Oct 7. Review.

Supplemental Content

Loading ...
Support Center